BRPI1006825A2 - compostos pró-neurogênicos - Google Patents
compostos pró-neurogênicosInfo
- Publication number
- BRPI1006825A2 BRPI1006825A2 BRPI1006825A BRPI1006825A BRPI1006825A2 BR PI1006825 A2 BRPI1006825 A2 BR PI1006825A2 BR PI1006825 A BRPI1006825 A BR PI1006825A BR PI1006825 A BRPI1006825 A BR PI1006825A BR PI1006825 A2 BRPI1006825 A2 BR PI1006825A2
- Authority
- BR
- Brazil
- Prior art keywords
- pro
- neurogenesis
- neurogenic compounds
- postnatal
- neurogenic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
Abstract
compostos pró-neurogênicos, composição farmacêutica e seu uso a presente invenção refere-se em geral a estimular neurogênese (por exemplo, neurogênese pós-natal, por exemplo, neurogênese hipocampal pós-natal) e proteger de morte de célula neuronal.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14375509P | 2009-01-09 | 2009-01-09 | |
PCT/US2010/020681 WO2010081115A1 (en) | 2009-01-09 | 2010-01-11 | Pro-neurogenic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI1006825A2 true BRPI1006825A2 (pt) | 2019-04-24 |
Family
ID=42224725
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI1006825A BRPI1006825A2 (pt) | 2009-01-09 | 2010-01-11 | compostos pró-neurogênicos |
Country Status (9)
Country | Link |
---|---|
US (4) | US8604074B2 (pt) |
EP (1) | EP2385829B1 (pt) |
JP (1) | JP5766614B2 (pt) |
CN (2) | CN107595841A (pt) |
AU (1) | AU2010203356B2 (pt) |
BR (1) | BRPI1006825A2 (pt) |
CA (1) | CA2748813C (pt) |
IL (1) | IL213992A (pt) |
WO (1) | WO2010081115A1 (pt) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2007139634A (ru) | 2007-10-25 | 2009-04-27 | Сергей Олегович Бачурин (RU) | Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения |
RU2544856C2 (ru) | 2008-01-25 | 2015-03-20 | Сергей Олегович Бачурин | НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
CL2009000725A1 (es) | 2008-03-24 | 2009-05-29 | Medivation Technologies Inc | Compuestos derivados de heterociclos con uniones puente sustituidos, moduladores de receptores adrenergicos, de serotonina, de dopamina y de histaminas; composicion farmaceutica; kit farmaceutico; y su uso en el tratamiento del trastorno cognitivo y trastorno psicotico. |
US8338447B2 (en) | 2008-03-24 | 2012-12-25 | Medivation Technologies, Inc. | Pyrido[3,4-B]indoles and methods of use |
WO2010051503A1 (en) | 2008-10-31 | 2010-05-06 | Medivation Technologies, Inc. | Azepino [4, 5-b] indoles and methods of use |
US9962368B2 (en) | 2009-01-09 | 2018-05-08 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
BRPI1006825A2 (pt) | 2009-01-09 | 2019-04-24 | Univ Texas | compostos pró-neurogênicos |
US8362277B2 (en) | 2009-01-09 | 2013-01-29 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
US9162980B2 (en) | 2009-01-09 | 2015-10-20 | Board Of Regents Of The University Of Texas System | Anti-depression compounds |
AU2010242910B2 (en) | 2009-04-29 | 2015-11-12 | Medivation Technologies, Inc. | Pyrido [4,3-b] indoles and methods of use |
JP5791612B2 (ja) | 2009-09-23 | 2015-10-07 | メディベイション テクノロジーズ, インコーポレイテッド | ピリド[3,4−b]インドールおよび使用方法 |
WO2011038164A1 (en) | 2009-09-23 | 2011-03-31 | Medivation Technologies, Inc. | Bridged heterocyclic compounds and methods of use |
CN102711468B (zh) | 2009-09-23 | 2014-07-09 | 梅迪维新技术公司 | 吡啶并[4,3-b]吲哚化合物及其使用方法 |
WO2011103485A1 (en) | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
WO2011103460A1 (en) | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]ondole derivatives and methods of use |
US9034865B2 (en) | 2010-02-18 | 2015-05-19 | Medivation Technologies, Inc. | Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
WO2011103430A1 (en) | 2010-02-19 | 2011-08-25 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
JP6126528B2 (ja) * | 2010-07-07 | 2017-05-10 | ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムThe Board Of Regents Of The University Of Texas System | 神経新生促進化合物 |
JP2014505737A (ja) | 2011-02-18 | 2014-03-06 | メディベイション テクノロジーズ, インコーポレイテッド | 糖尿病を処置する化合物および方法 |
WO2012112964A2 (en) | 2011-02-18 | 2012-08-23 | Medivation Technologies, Inc. | PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE |
US20140155384A1 (en) | 2011-02-18 | 2014-06-05 | Medivation Technologies, Inc. | Compounds and methods of treating diabetes |
US9434747B2 (en) | 2011-02-18 | 2016-09-06 | Medivation Technologies, Inc. | Methods of treating diabetes |
AU2012338362B2 (en) | 2011-11-15 | 2017-05-18 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Tricyclic compounds, compositions comprising them and uses thereof |
SG11201407402TA (en) | 2012-05-11 | 2014-12-30 | Reset Therapeutics Inc | Carbazole-containing sulfonamides as cryptochrome modulators |
CA2882826A1 (en) | 2012-08-24 | 2014-02-27 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
WO2014031125A1 (en) | 2012-08-24 | 2014-02-27 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
US9353078B2 (en) * | 2013-10-01 | 2016-05-31 | New York University | Amino, amido and heterocyclic compounds as modulators of rage activity and uses thereof |
US9902713B2 (en) | 2013-11-11 | 2018-02-27 | Board Of Regents Of The University Of Texas System | Neuroprotective compounds and use thereof |
WO2015070237A1 (en) | 2013-11-11 | 2015-05-14 | Board Of Regents Of The University Of Texas System | Neuroprotective chemicals and methods for identifying and using same |
US9119832B2 (en) | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
TWI690521B (zh) | 2014-04-07 | 2020-04-11 | 美商同步製藥公司 | 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類 |
PT3288637T (pt) | 2015-04-28 | 2022-10-11 | Newsouth Innovations Pty Ltd | Visar nad+ para tratar comprometimento cognitivo, neuropatias e inatividade induzidos por quimioterapia e radioterapia |
CN104974141B (zh) * | 2015-07-27 | 2017-04-05 | 西南大学 | 咔唑四唑类衍生物及其制备方法和应用 |
US20170121385A1 (en) | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
US11007178B2 (en) | 2016-03-18 | 2021-05-18 | University Of South Florida | Methods and uses of Nampt activators for treatment of diabetes, cardiovascular diseases, and symptoms thereof |
MX2021010193A (es) | 2019-02-27 | 2021-09-21 | Univ California | Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales. |
CN113402444B (zh) * | 2021-06-17 | 2024-05-03 | 上海欧坤生物医药科技有限公司 | 一种咔唑类化合物及其在制备治疗脂肪肝及2型糖尿病等代谢相关疾病药物中的应用 |
Family Cites Families (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE539438A (pt) | 1954-07-01 | |||
US3518250A (en) | 1965-12-17 | 1970-06-30 | Ibm | Substitution of imino-heterocyclic compounds |
US3409628A (en) | 1966-05-12 | 1968-11-05 | Hoffmann La Roche | 5-(3-pyridylethyl)pyridoindole derivatives |
US4495281A (en) | 1982-10-21 | 1985-01-22 | Miles Laboratories, Inc. | Tricyclic antidepressant drug immunogens, antibodies, labeled conjugates, and related derivatives |
JPH04217657A (ja) | 1990-10-19 | 1992-08-07 | Toyo Gosei Kogyo Kk | 4‐(n‐アリールカルバモイルアルキルチオ)フェノール系化合物及びこれを用いた感熱記録材料 |
JP2684252B2 (ja) | 1991-03-08 | 1997-12-03 | 富士写真フイルム株式会社 | ハロゲン化銀カラー写真感光材料 |
US6194439B1 (en) | 1991-05-29 | 2001-02-27 | Pfizer Inc. | Tricyclic polyhydroxylic tyrosine kinase inhibitors |
US5234923A (en) | 1991-12-16 | 1993-08-10 | E. R. Squibb & Sons, Inc. | Substitute indole and benzimidazole derivatives |
EP0823905A1 (en) | 1995-05-05 | 1998-02-18 | Novo Nordisk A/S | Novel heterocyclic chemistry |
RU2106864C1 (ru) | 1995-10-23 | 1998-03-20 | Николай Серафимович Зефиров | Средство для лечения болезни альцгеймера |
WO1998015546A1 (en) | 1996-10-04 | 1998-04-16 | Novo Nordisk A/S | N-substituted azaheterocyclic compounds |
US6468996B1 (en) * | 1998-10-21 | 2002-10-22 | Novo Nordisk A/S | Substituted hetero-polycyclic compounds as PPARα and PPARγ activators |
WO2000023425A1 (en) | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | New compounds, their preparation and use |
EP1192178A2 (en) | 1999-06-21 | 2002-04-03 | Eli Lilly And Company | Rufomycins and derivatives thereof useful as inhibitors of multi-drug resistance associated protein-1 (mrp-1) |
MY125942A (en) | 1999-09-07 | 2006-09-29 | Upjohn Co | Aminoalkoxy carbazoles for the treatment of cns diseases |
EP1094063A1 (en) | 1999-10-18 | 2001-04-25 | Applied Research Systems ARS Holding N.V. | 9-(Piperazinylalkyl)carbazoles as Bax-modulators |
GB9925880D0 (en) * | 1999-11-01 | 1999-12-29 | British Tech Group Int | B-Carboline derivatives |
DE60131138T2 (de) | 2000-01-13 | 2008-08-14 | Amgen Inc., Thousand Oaks | Antibakterielle mittel |
EP1125925A1 (en) | 2000-02-15 | 2001-08-22 | Applied Research Systems ARS Holding N.V. | Amine derivatives for the treatment of apoptosis |
US6340548B1 (en) | 2000-03-16 | 2002-01-22 | Imation Corp. | Organophotoreceptors for electrophotography featuring novel charge transport compounds |
JP2003529584A (ja) | 2000-03-27 | 2003-10-07 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ | Bax阻害剤としての医薬として活性なピロリジン誘導体 |
WO2002038142A2 (en) | 2000-11-08 | 2002-05-16 | Massachusetts Institute Of Technology | Serotonergic compositions and methods for treatment of mild cognitive impairment |
WO2002060867A2 (en) | 2001-01-29 | 2002-08-08 | Insight Strategy And Marketing Ltd | Carbazole derivatives and their uses as heparanase inhibitors |
WO2003007070A1 (en) | 2001-07-13 | 2003-01-23 | The University Of Chicago | Novel nonlinear optical polymers incorporating amines |
EP1414819B1 (en) | 2001-08-08 | 2005-10-12 | Pharmacia & Upjohn Company LLC | THERAPEUTIC 1H-PYRIDO[4,3-b]INDOLES |
US6835513B2 (en) | 2002-03-28 | 2004-12-28 | Samsung Electronic Co., Ltd. | Carbazole based charge transport compounds |
US6864025B2 (en) | 2002-03-28 | 2005-03-08 | Samsung Electronics Co., Ltd. | Sulfonyldiphenylene-based charge transport compositions |
MXPA04010555A (es) | 2002-04-25 | 2005-02-17 | Pharmacia Corp | Acidos piperidinil- y piperazinil-sulfonilmetil hidroxamicos y su uso como inhibidores de proteasa. |
US7977049B2 (en) | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
DK1569929T3 (da) | 2002-12-10 | 2010-08-16 | Virochem Pharma Inc | Forbindelser og fremgangsmåder til behandling eller forebyggelse af flavi-virusinfektioner |
CN100503607C (zh) | 2003-06-02 | 2009-06-24 | 新疆华世丹药物研究有限责任公司 | 去氢骆驼蓬碱衍生物类化合物及其应用 |
US7582773B2 (en) | 2003-09-25 | 2009-09-01 | Wyeth | Substituted phenyl indoles |
EP1680431A1 (en) | 2003-10-17 | 2006-07-19 | Rigel Pharmaceuticals, Inc. | Benzothiazole and thiazole'5,5-b!pyridine compositions and their use as ubiquitin ligase inhibitors |
GB0324551D0 (en) | 2003-10-21 | 2003-11-26 | Karobio Ab | Novel compounds |
EP1689389A4 (en) * | 2003-12-04 | 2009-06-17 | Nat Health Research Institutes | Indole compounds |
RU2283108C2 (ru) | 2003-12-08 | 2006-09-10 | Сергей Олегович Бачурин | ГЕРОПРОТЕКТОР НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
US20070196395A1 (en) | 2003-12-12 | 2007-08-23 | Mackerell Alexander | Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain |
AU2004315111B2 (en) | 2004-01-29 | 2010-03-04 | Cellzome Ag | Treatment of neurodegenerative diseases by the use of GPR49 |
US20070185152A1 (en) | 2004-03-02 | 2007-08-09 | Smithkline Beecham Corporation | Inhibitors of akt activity |
US20050244674A1 (en) | 2004-04-28 | 2005-11-03 | Jsr Corporation | Phosphorescent polymer and production process thereof, organic electroluminescence device, and metal conplex-containing compond and production process thereof |
US7445877B2 (en) | 2004-06-10 | 2008-11-04 | Samsung Electronics Co., Ltd. | Charge transport materials having a central disulfane linkage |
CN1738069A (zh) | 2004-08-17 | 2006-02-22 | 国际商业机器公司 | 其电极具有增强注入特性的电子器件制造方法和电子器件 |
WO2006041624A2 (en) | 2004-09-20 | 2006-04-20 | Washington University | Nad biosynthesis systems |
CN101035526A (zh) | 2004-10-13 | 2007-09-12 | 默克公司 | 用于治疗高眼压的眼用组合物 |
EP1809275A1 (en) | 2004-10-13 | 2007-07-25 | Smithkline Beecham Corporation | Chemical compounds |
WO2006077954A1 (ja) * | 2005-01-21 | 2006-07-27 | Kyowa Hakko Kogyo Co., Ltd. | 神経疾患治療剤 |
CA2599987A1 (en) | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Fused heterocyclic compounds and their use as sirtuin modulators |
EP1877352A4 (en) | 2005-04-15 | 2009-01-21 | Tgen | METHODS, COMPOUNDS AND COMPOSITIONS WITH GENOTYPE SELECTIVE ANTICANCER ACTIVITY |
WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
US20070117834A1 (en) | 2005-10-04 | 2007-05-24 | David Hung | Methods and compositions for treating Huntington's disease |
US7438916B2 (en) | 2005-10-14 | 2008-10-21 | Virginia Tech Intellectual Properties, Inc. | Therapeutic target for protozoal diseases |
US8106184B2 (en) | 2005-11-18 | 2012-01-31 | Cornell University | Nicotinoyl riboside compositions and methods of use |
AU2006318212C1 (en) | 2005-11-23 | 2012-08-30 | The Board Of Regents Of The University Of Texas System | Oncogenic ras-specific cytotoxic compound and methods of use thereof |
DE102005062741A1 (de) | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Ag | Fluorene und Carbazole als Liganden des EP2 Rezeptors |
WO2007079239A2 (en) | 2005-12-30 | 2007-07-12 | Acadia Pharmaceuticals Inc. | Bicyclic nitrogen compounds as modulators of ghrelin receptor and uses thereof |
KR100814109B1 (ko) | 2006-01-09 | 2008-03-14 | 한국생명공학연구원 | 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 약학적 조성물 |
US20070203236A1 (en) | 2006-01-11 | 2007-08-30 | Smith Jeffrey W | Novel antagonists of the human fatty acid synthase thioesterase |
RU2338537C2 (ru) | 2006-01-25 | 2008-11-20 | Сергей Олегович Бачурин | СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ШИЗОФРЕНИИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
US20090088449A1 (en) * | 2006-02-07 | 2009-04-02 | Mitsubishi Tanabe Pharma Corporation | 4-acylaminopyridine derivative mediated neurogenesis |
JP2007223916A (ja) * | 2006-02-21 | 2007-09-06 | Institute Of Physical & Chemical Research | 抗菌剤 |
US7807704B2 (en) | 2006-03-30 | 2010-10-05 | Chemocentryx, Inc. | Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 |
EP2382975A3 (en) * | 2006-05-09 | 2012-02-29 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
MX2008014843A (es) | 2006-05-22 | 2008-12-05 | Vanda Pharmaceuticals Inc | Tratamiento de trastornos depresivos. |
WO2008021745A2 (en) | 2006-08-16 | 2008-02-21 | Itherx Pharmaceuticals, Inc. | Hepatitis c virus entry inhibitors |
MX2009002496A (es) * | 2006-09-08 | 2009-07-10 | Braincells Inc | Combinaciones que contienen un derivado de 4-acilaminopiridina. |
RU2329044C1 (ru) | 2006-11-16 | 2008-07-20 | Андрей Александрович Иващенко | Лиганды 5-ht6 рецепторов, фармацевтическая композиция, способ ее получения и лекарственное средство |
RU2338745C1 (ru) | 2007-03-21 | 2008-11-20 | Андрей Александрович Иващенко | ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1Н-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
RU2339637C1 (ru) | 2007-04-05 | 2008-11-27 | Андрей Александрович Иващенко | Блокаторы гистаминного рецептора для фармацевтических композиций, обладающих противоаллергическим и аутоиммунным действием |
RU2334747C1 (ru) | 2007-04-05 | 2008-09-27 | Андрей Александрович Иващенко | ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1Н-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
JP5540701B2 (ja) | 2007-06-21 | 2014-07-02 | コニカミノルタ株式会社 | 有機エレクトロルミネッセンス素子材料 |
MX2010003230A (es) | 2007-09-25 | 2010-04-07 | Topotarget Uk Ltd | Metodos para la sintesis de ciertos compuestos de acido hidroxamico. |
CN101139347B (zh) | 2007-10-15 | 2010-11-24 | 新疆华世丹药物研究有限责任公司 | 去氢骆驼蓬碱衍生物类化合物及其应用 |
RU2007139634A (ru) | 2007-10-25 | 2009-04-27 | Сергей Олегович Бачурин (RU) | Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения |
CN101429198B (zh) | 2007-11-09 | 2013-10-23 | 新疆华世丹药物研究有限责任公司 | 去氢骆驼蓬碱衍生物及其应用 |
EP2236511A4 (en) | 2007-12-21 | 2011-04-13 | Alla Chem Llc | LIGANDS OF ALPHA ADRENOCEPTORS AND OF DOPAMINE, HISTAMIN, IMIDAZOLIN AND SEROTONIN RECEPTORS AND THEIR APPLICATION THEREOF |
CA2709784A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
RU2544856C2 (ru) | 2008-01-25 | 2015-03-20 | Сергей Олегович Бачурин | НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
US9079999B2 (en) | 2008-02-26 | 2015-07-14 | Rigoberto Advincula | Methods for preparing polymer coatings by electrochemical grafting of polymer brushes, compositions prepared thereby and compositions for preparing the coatings |
US8338447B2 (en) | 2008-03-24 | 2012-12-25 | Medivation Technologies, Inc. | Pyrido[3,4-B]indoles and methods of use |
US7989127B2 (en) | 2008-04-30 | 2011-08-02 | Xerox Corporation | Carbazole containing charge transport layer photoconductors |
KR20110081862A (ko) | 2008-10-22 | 2011-07-14 | 제넨테크, 인크. | 축삭 변성의 조절 |
WO2010051503A1 (en) | 2008-10-31 | 2010-05-06 | Medivation Technologies, Inc. | Azepino [4, 5-b] indoles and methods of use |
AR073923A1 (es) | 2008-10-31 | 2010-12-09 | Medivation Technologies Inc | Pirido( 4,3-b) indoles que contienen restos rigidos |
BRPI1006825A2 (pt) | 2009-01-09 | 2019-04-24 | Univ Texas | compostos pró-neurogênicos |
US8362277B2 (en) | 2009-01-09 | 2013-01-29 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
US9162980B2 (en) | 2009-01-09 | 2015-10-20 | Board Of Regents Of The University Of Texas System | Anti-depression compounds |
US9962368B2 (en) | 2009-01-09 | 2018-05-08 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
JP5827943B2 (ja) | 2009-04-29 | 2015-12-02 | メディベイション テクノロジーズ, インコーポレイテッド | ピリド[4,3−b]インドールおよびその使用方法 |
US8763653B2 (en) | 2009-08-06 | 2014-07-01 | Harro Höfliger Verpackungsmaschinen GmbH | Filling assembly for metering powder and method for operating such a filling assembly |
EP2480079A4 (en) | 2009-09-23 | 2015-04-08 | Medivation Technologies Inc | PYRIDO- (3,4-B-) INDOLE AND USE METHOD THEREFOR |
US8927538B2 (en) | 2010-03-22 | 2015-01-06 | Council Of Scientific & Industrial Research | Carbazole linked pyrrolo[2,1-c][1,4]benzodiazefine hybrids as potential anticancer agents and process for the preparation thereof |
JP6126528B2 (ja) | 2010-07-07 | 2017-05-10 | ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムThe Board Of Regents Of The University Of Texas System | 神経新生促進化合物 |
WO2012067963A1 (en) | 2010-11-15 | 2012-05-24 | Abbott Laboratories | Nampt inhibitors |
JP6254087B2 (ja) | 2011-10-15 | 2017-12-27 | ジェネンテック, インコーポレイテッド | 癌を治療するためのscd1アンタゴニスト |
WO2014031125A1 (en) | 2012-08-24 | 2014-02-27 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
CA2882826A1 (en) | 2012-08-24 | 2014-02-27 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
US9789096B2 (en) | 2013-09-04 | 2017-10-17 | Board Of Regents Of The University Of Texas System | Methods and compositions for selective and targeted cancer therapy |
US9902713B2 (en) | 2013-11-11 | 2018-02-27 | Board Of Regents Of The University Of Texas System | Neuroprotective compounds and use thereof |
WO2015070237A1 (en) | 2013-11-11 | 2015-05-14 | Board Of Regents Of The University Of Texas System | Neuroprotective chemicals and methods for identifying and using same |
-
2010
- 2010-01-11 BR BRPI1006825A patent/BRPI1006825A2/pt not_active Application Discontinuation
- 2010-01-11 CA CA2748813A patent/CA2748813C/en not_active Expired - Fee Related
- 2010-01-11 US US12/685,652 patent/US8604074B2/en not_active Expired - Fee Related
- 2010-01-11 JP JP2011545499A patent/JP5766614B2/ja not_active Expired - Fee Related
- 2010-01-11 AU AU2010203356A patent/AU2010203356B2/en not_active Ceased
- 2010-01-11 WO PCT/US2010/020681 patent/WO2010081115A1/en active Application Filing
- 2010-01-11 CN CN201710811262.XA patent/CN107595841A/zh active Pending
- 2010-01-11 CN CN201080007207.1A patent/CN102405043B/zh not_active Expired - Fee Related
- 2010-01-11 EP EP10711784.8A patent/EP2385829B1/en not_active Not-in-force
-
2011
- 2011-07-07 IL IL213992A patent/IL213992A/en active IP Right Grant
-
2013
- 2013-12-09 US US14/100,515 patent/US9278923B2/en not_active Expired - Fee Related
-
2014
- 2014-07-24 US US14/339,742 patent/US9156787B2/en not_active Expired - Fee Related
-
2016
- 2016-01-15 US US14/996,596 patent/US10172827B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US10172827B2 (en) | 2019-01-08 |
CA2748813C (en) | 2018-07-10 |
US20160206594A1 (en) | 2016-07-21 |
US8604074B2 (en) | 2013-12-10 |
US20150057301A1 (en) | 2015-02-26 |
IL213992A0 (en) | 2011-08-31 |
EP2385829A1 (en) | 2011-11-16 |
JP5766614B2 (ja) | 2015-08-19 |
AU2010203356A1 (en) | 2011-08-04 |
EP2385829B1 (en) | 2018-08-01 |
AU2010203356B2 (en) | 2015-11-26 |
IL213992A (en) | 2016-04-21 |
CA2748813A1 (en) | 2010-07-15 |
US20110015217A1 (en) | 2011-01-20 |
US9278923B2 (en) | 2016-03-08 |
CN102405043B (zh) | 2017-08-22 |
CN102405043A (zh) | 2012-04-04 |
CN107595841A (zh) | 2018-01-19 |
WO2010081115A1 (en) | 2010-07-15 |
US9156787B2 (en) | 2015-10-13 |
US20140094480A1 (en) | 2014-04-03 |
JP2012515166A (ja) | 2012-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI1006825A2 (pt) | compostos pró-neurogênicos | |
CL2007002682A1 (es) | Compuestos derivados de 4-metilpiridopirimidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el crecimiento anormal de celulas, como cancer. | |
CO6321189A2 (es) | Compuestos de tiazol y oxazol de bencen-sulfonamida | |
AR088622A1 (es) | 18-METIL-6,7-METILEN-3-OXO-17-PREGN-4-EN-21,17b-CARBOLACTONA, PREPARADOS FARMACEUTICOS QUE CONTIENEN LOS COMPUESTOS MENCIONADOS Y SU USO EN LA TERAPIA DE LA ENDOMETRIOSIS | |
CL2013002517A1 (es) | Compuestos derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso en el tratamiento o profilaxis del cancer. | |
CR20150326A (es) | Inhibidores de autotaxina | |
PA8827101A1 (es) | Derivados de indazoles sustituidos con fenilo o piridinilo | |
CL2012000752A1 (es) | Compuestos derivados de fenilpiri(mi)dinilpirazoles para el control de microorganismos no deseados en la proteccion de plantas y compuestos intermediarios. | |
GT200800250A (es) | Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina | |
ECSP12012318A (es) | Inhibidores de pirazolil quinazolina cinasa | |
GT200900230A (es) | 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso | |
UY33396A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
CR20120283A (es) | Inhibidor de bromodominio de benzodiazepina | |
CL2013001964A1 (es) | Compuestos derivados de heterociclos, como inhibidores de bace 1 o 2; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento o prevencion de la enfermedad de alzheimer o deterioro cognitivo leve, resistencia a la insulina, diabetes tipo 2, entre otras. | |
CL2008003188A1 (es) | Compuestos derivados de piridina y pirazina; composicion farmaceutica que los comprende;y su uso en el tratamiento o prevencion de tumores sensibles a la inhibicion de enzimas del receptor ax1 y/o c-met. | |
CR20110080A (es) | 4-fenil-1h-pirazoles insecticidas | |
CL2007000311A1 (es) | Compuestos derivados de cromen-2-ona; composicion farmaceutica que los comprende;y su uso en el trastamiento de un trastorno proliferativos como es el cancer. | |
MX2012007098A (es) | Derivados fenolicos y su uso farmaceutico o cosmetico. | |
UY32659A (es) | Pirazinilpirazoles | |
CR11684A (es) | Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa | |
BR112016011755A2 (pt) | derivado de ureia ou sal farmacologicamente aceitável do mesmo | |
MX2012007161A (es) | Derivados fenolicos y su uso farmaceutico o cosmetico. | |
BR112013029256A8 (pt) | combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2 | |
ECSP088745A (es) | Derivados sustituidos de cromanol y su uso | |
CO6470899A2 (es) | 2,4-diaminopirimidinas para el tratamiento de enfermedades caracterizadas por proliferación celular excesiva o normal |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |